Business · 04/08/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Dostinex Tablets Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Dostinex Tablets, a human drug product, following a submission to the US Department of Commerce's Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →